Home » Blog » Formula Shortage Update: November 2022

Formula Shortage Update: November 2022

If you are formula feeding your baby right now, odds are you are constantly searching for the newest formula update. There have been changes to processes, new formulas available, and a lot of finger pointing.

Chances are that if you are formula feeding, you also don’t have the time to research all the new updates as they come. It feels like there are new updates every few days!

This post may contain affiliate links and when you click on the links I may earn a small commission at no charge to you. As an Amazon affiliate, I earn a commission from qualifying purchases.

Backstory and Updates

In short, there are a lot of regulations around infant formula (which is good!). This means that it can be very difficult for new companies to enter the scene. We’ve had 2 in the past couple of years, but for the most part, there are only a handful of factories that can make formula in the US. This means when one shuts down, it’s a big deal.

In February, Abbott (which makes Similac products) voluntarily recalled several formulas and closed one of their manufacturing sites. Because the demand for formula is pretty stable, the other formula producing facilities were not able to ramp up production to make up for one site being closed. They were already dealing with supply chain issues.

November 2022

On November 2, the FDA released a statement stating that more imports were coming. They approved Danone Aptamil Care Stage 1 and 2 as well as the a2 Milk Company a2 Platinum Infant Formula and Follow On Formula.

On November 14, the FDA released a statement stating that Nutricia UCD Anamix Infant Formula would be imported. This is a metabolic formula for infants with urea cycle disorders.

On November 15, the FDA released an outline of their strategy to help prevent Cronobacter illnesses associated with infant formula. It includes things such as considering specialty staff to conduct infant formula inspections and providing additional training to staff. Improving communication to consumers about safe formula preparation and storage (check out my e-book if you want to learn more). Most importantly, there’s discussion of elevating Cronobacter infection among infants as a nationally notifiably disease. This would help alert the FDA and other regulatory agencies of outbreaks in real time, versus trying to put the puzzle pieces together after the fact.

To add to the confusion, on November 17, Amazon mistakenly sent an email stating there was another recall of Abbott products. Abbott put out a statement stating that there has been no further recalls at this time.

June 2022

As of June 4, Abbott is restarting infant formula production. The focus will be on Elecare and specialty formulas. They expect the formulas to be available to consumers around June 20. This is great news, but we’re not out of the woods quite yet. As of June 15, Abbott closed the plant in Michigan again due to severe thunderstorms and heavy rains causing wind, hail, power outages, and flood damage. Abbott has stated that they will conduct comprehensive testing with an independent third party and the FDA prior to restarting production again. They expect another delay of a few weeks.

July 2022

Although there hasn’t been an official statement from Similac as of yet, the Michigan plant reopened July 1. The focus continues to be on Elecare, a hypoallergenic formula. Abbott did not officially release a statement until August 26th.

As of July 6, the FDA is developing a plan to keep the international formulas on our shelves indefinitely. More information on that should be coming out in the fall. There was mention that there needs to be a plan to streamline approval for domestic companies, but no further details on how that would be accomplished. In general, more competition should lead to lower prices and better quality all around.

August 2022

On August 25th, the White House announced that they have sourced several shipments of Gerber Good Start Gentle formulas from Mexico to Texas.

On August 26th, Abbott released a statement stating that they restarted the Similac production in Michigan. They estimate that it will take around 6 weeks for product to hit shelves. They have quality systems in place that can detect cronobacter. If detected, they will suspend production and work with the FDA before restarting. This has happened already, showing the quality systems in place work.

September 2022

On September 16, the White House announced that they were shipping in Alfamino Infant and Alfamino Jr. from Switzerland. It will be distributed to hospitals and home care providers, since these formulas are designed for kids who can’t tolerate standard formulas.

The FDA released an evaluation of their response to the crisis. It outlined issues and recommendations for improvements in the long run. One key missing recommendation (to me and many other feeding experts) was labeling Cronobacter as a nationally reportable disease which could alert officials of formula issues much sooner. I’ve outlined the report below.

On 9/30 the FDA announced a pathway to support international formulas staying in the US long term. This should help diversify the market and hopefully prevent future shocks to the system in cases of emergency. Currently the guidance extends their allowance until January 6, 2023 or later. Per the statement, if the companies send a letter stating their intent to pursue regulatory requirements, “the FDA does not intend to object to the continued marketing of covered infant formulas in the US through October 2025.” Companies will be expected to meet FDA regulations during this time.

October 2022

Kendamil, Aptamil, and AussieBubs have released statements stating that they have sent in their letter of intent to pursue regulatory requirements.

Per an FDA call, the current guidance is in effect through October 18, 2025. There is a 5 phase plan with the goal of diversifying the US infant formula market which should help prevent a shortage in the future. The goal currently is for infants started on a formula to be able to continue to use the formula for as long as they need to. More information on the 5 phases of the plan will be released.

The FDA is still accepting applications for enforcement discretion. If there are international formulas who do NOT submit a letter, they can still continue importing product until December 2022. The product can remain on the shelves until it sells out or expires.

On October 14, Abbott issued a voluntary recall on several ready to feed 2 ounce formulas including: Similac Pro-Total Comfort, Similac 360 Total Care, Similac 360 Total Care Sensitive, Similac Special Care 24, Similac NeoSure, Similac Sterilized Water, and Pedialyte Electrolyte Solution. The recall does not include any powdered formula or any liquid formula in other sizes. It will mostly affect hospitals and other medical facilities.

On October 21, the FDA held a webinar titled Infant Formula Discretion Transition Guidance Overview. Recordings are available. The webinar reviewed the guidelines provided on September 30.

The basic timeline for companies is that they must submit their letter of intent by December 5 (some have already done). They must submit their plan for meeting the new infant formula requirements by February 28th, 2023. By June 16, 2023, they must submit a plan to show that their formula promotes adequate growth in babies and data showing that the protein is of sufficient biological quality. They must provide the data showing adequate growth in 2024. They will submit the final formula in 2024 or 2025 depending on their timelines.

There are two broad groups: exempt and non-exempt formulas. Exempt formulas are designed for babies with inborn errors of metabolism, low birth weight, or other special medical or dietary problems. Within this group, they may or may not require a clinical study, so their due dates will depend on that. The non-exempt formulas are designed for term babies. Within this group, companies can either comply with GMS requirements or apply for exemptions or provide an alternative study design. Their due dates will be different based on the route they take.

PhaseAction ItemDue Date
1Letter of Intent12/5/2022
2Plan for Meeting Formula Requirements2/28/2023
3Data Showing Sufficient Biological Quality of Protein and Plan for Data Showing Normal GrowthExempt: 8/1/2023
Non-Exempt: 6/16/2023
4Data Demonstrating Normal GrowthExempt: 1/5/2024 if clinical study is not required or 6/6/2025 if clinical study is required
Non-Exempt: 1/5/2024 if using a narrative explanation on exemption from the GMS requirement or 9/6/2024 if providing a draft report of compliance or alternative study designs
5New Infant Formula SubmissionExempt: 2/16/2024 if clinical study is not required or 7/18/2025 if clinical study is required
Non-Exempt: 2/16/2024 if exempt from GMS requirements or 10/18/2024 if submission complies with GMS requirements or used an alternative study design
Exempt: specialty formulas designed for infants with inborn errors of metabolism, low birth weight or other special medical or dietary problems; Non-Exempt: standard formulas designed for term babies

FDA Evaluation of Infant Formula Response

In September, the FDA released an evaluation of their response to the infant formula crisis. It walked through the timeline of events and findings and recommendations. Overall, many people were underwhelmed by what the report found (or didn’t find). Much of what they reported were things that people in the field had noted months prior.

FDA Needs Modern Data Systems

The FDA reported that the technology they use is outdated and they recommend improving their processes so that people can be properly notified of public health threats. They noted inadequate processes related to whistleblower complaints resulting to delays in response. Their response was that they needed to clarify terms and offer training to staff that these incidents should be escalated. Lastly, they noted that some samples were delayed in transit by a third party and they recommended that they evaluate their procedures to see if improvements can be made.

FDA Needs to Optimize its Emergency Response Capabilities

The FDA noted a lack of training and operating procedures in case of emergencies, especially with food safety product-related emergencies. Their recommendation was training and increase trained staff for response, especially during multiple simultaneous public health emergencies. They noted that COVID 19 cases delayed in person response to complaints. Their recommendation was to gain authority to remotely access records or other information as needed. Given that this was a public health emergency, I feel that they should have procedures in place to enter facilities with known COVID 19 cases, as physicians and other medical staff had been doing since the beginning of the pandemic.

FDA Needs to Strengthen its Foods Workforce

The FDA noted that investigators conducting investigations of infant formula manufacturing facilities receive limited infant formula-specific training. They recommended a specialized training program. They noted that there has been a decrease in funding hindering their ability to keep pace with “the growing workload, increased complexity of supply chains, and scientific and technological changes in food manufacturing.” Lastly they noted that because infant formula is the sole source of nutrition for a population it presents unique challenges to public health compared to other food compliance actions. They are recommended to review procedures for critical food products to come up with a decision matrix to consider activities to minimize product availability concerns.

FDA Oversight Needs to Focus on Industry Accountability

The infant formula industry relies on dated technology and record keeping practices that was causing delays throughout the process. The FDA recommends to lay out plan for the infant formula industry to improve practices for the future. They noted that conditions at the facility were not consistent with a strong food safety culture and that the FDA does not have the authority, expertise, or resources to manage supply chain issues and shortages of critical food products.

FDA Needs to Work with Engaged Stakeholders to Close Scientific Gaps and Build a More Robust Regulatory Program

The FDA noted that Cronobacter is not a nationally reportable disease which can slow response time, however they did not recommend making it one. They instead recommended to learn more about it. They also noted that consumer education on the safe handling and preparation of infant formula is limited. I agree with this which is why I created my Formula Feeding Guide. The breastfeeding support we provide is great, but it often leaves out any education on formula.

Formula Options For Now

If you’re able to find your usual formula, great! Keep using it! Check out this guide to find out some of the basics of infant formula. For most babies, the most important thing to compare between formulas will be the protein. If your baby tolerates intact protein (standard formula), you’ll have many more options. If your baby is using partially broken down proteins, you’ll want to find a formula that’s similar.

it is incredibly rare for infants to be lactose intolerant. Lactose is the primary carbohydrate in breast milk. There are medical conditions, like galactosemia, where a baby cannot tolerate lactose, but if your baby is not tolerating their formula it’s *probably* not lactose causing the problem.

Companies can market a lower lactose formula as an option because many adults are lactose intolerant and intuitively it makes sense to us. They generally also change the protein in these formulas, so babies do tolerate them better.

Toddler Formula

The AAP stated that it is ok to use toddler formula for a short amount of time if unable to find infant formula. This is a tricky recommendation, because not all toddler formulas are the same. There are actually a few that meet all the requirements of infant formula, so I would recommend starting with those first. Talk to your pediatrician before starting any toddler formula.

International Formulas

We now have some international formulas available. Some of these companies have released official statements that they plan on applying to stay in the US long term. There are a lot of great options available.


Hopefully this crisis will lead to some systemic changes. It would be great if these toddler formulas could be marketed and regulated as infant formulas. It would also be nice if we could safely import international formulas without a crisis.

If you’re looking for more basic information on formula feeding, check out my Formula Feeding Guide. It covers the basics from choosing a formula, bottle, water to how to feed and how much to feed.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top